Does sotalol have reverse-use dependence during tachyarrhythmias?

American Journal of Cardiology

Volumn 78, Issue 2, 1996, Pages 247-250

  Kovoor, Pramesh ^a   Byth, Karen ^a   Uther, John B ^a   Ross, David L ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; SOTALOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART CYCLE; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 0030055495     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)90409-9     Document Type: Article

References (15)

1. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82: 2235-2242.
2. Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. Pharmacol Exp Ther 1985;232:817-825.
3. Weidmann S. The effect of the cardiac membrane potential on the rapid availability of the sodium carrier system. J Physiol Lond 1955;127:213-223.
4. Weidmann S. Effects of calcium ions and local anaesthetics on electrical properties of purkinje fibers. J Physiol Lond 1955;129:568-582.
5. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690.
6. Strauss HC, Bigger JT, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res 1970;26:661-678.
7. Solomon AJ, Syn D, Barbey JT. A simple in vivo model to evaluate the effects of antiarrhythmic agents. PACE 1992;15:2092-2096.
8. Schmitt C, Brachmann J, Karch M, Waldecker B, Navarrete L, Montera M, Beyer T, Kubler W. Reverse use-dependence effects of sotalol demonstrated by recording monophasic action potentials of the right ventricle. Am J Cardiol 1991;68:1183-1187.
9. Ho DSW, Zecchin RP, Richards DAB, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994;344:18-23.
10. Camm JA, Paul V. Sotalol for paroxysmal supraventricular tachycardias. Am J Cardiol 1990;65:67A-73A.
11. Borggrefe M, Breithardt G. Electrophysiologic effect of sotalol in supraventricular tachycardias. Z Kardiol 1985;74:506-511.
12. Feld GK, Venkat N, Singh BN. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine and lidocaine and significance of changes in refractoriness and conduction. Circulation 1986;74:197-204.
13. Huikuri HV, Yli-Mayry S. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. PACE 1992;15:2103-2107.
14. Singh B, Kehoe R, Woosley RL, Scheinman M, Quart B. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Am Heart J 1995;129:87-97.
15. Hayward RP, Taggart P. Effect of Sotalol on human atrial action potential duration and refractoriness: cycle length dependency of class III activity. Cardiovasc Res 1986;20:100-107.